



**NEWS ANNOUNCEMENT  
CONTACTS:**

**FOR IMMEDIATE RELEASE**

**STERIS: Robin Baum; 440-392-7428, [robin\\_baum@steris.com](mailto:robin_baum@steris.com)**

**NeoForce: Nancy St. Clair; 215-672-6800, [nancy.stclair@neoforcegroup.com](mailto:nancy.stclair@neoforcegroup.com)**

**STERIS CORPORATION AND NEOFORCE GROUP SIGN COLLABORATION  
AGREEMENT TO BROADEN SURGICAL SOLUTION OPTIONS FOR WORLD'S  
SMALLEST PATIENTS**

*The two Companies will co-market the world's first integrated neonatal surgical system*

**MENTOR, OHIO – December 3, 2009** – STERIS Corporation (NYSE: STE) and NeoForce Group, Inc. (Ivyland, PA) today announced their agreement to jointly promote the world's first dedicated surgical system for term and preterm newborns. The new system includes a dedicated neonatal surgical table, customized visualization and integration technology, full procedural capability, and enhanced connectivity to families and medical professionals outside the room.

In the unique environment of the neonatal intensive care unit (NICU), it is better to locate the surgical environment near the babies rather than to try to adapt an adult OR suite into a mini NICU and transport a fragile newborn there. In 2008, NeoForce began working with the medical staff at Rainbow Babies and Children's Hospital in Cleveland, Ohio to design a surgical table system that could address the unique needs and challenges surgeons face when performing surgery on the world's smallest patients. STERIS was called into the project to integrate high performance lighting, visualization and connectivity technologies with the table. The resulting collaboration led to a wholistic neonatal surgical solution.

“As we developed our Rainbow Flex™ Surgical Table, we had to assure that our designs would harmonize with the other devices in the OR. STERIS caught our attention with their superior lighting, integration and casework solutions,” commented Otho Boone, President of NeoForce. “Working with STERIS in a cooperative framework brings the strengths of both companies together for the ultimate benefit of our customers and their tiny patients.”

Bill O’Riordan, vice president and general manager of the Surgical Solutions business at STERIS, adds, “As hospitals focus on processes that reduce costs and improve outcomes,

integrated solutions will bring technology to patients in special care areas rather than transporting them between departments. This collaboration will provide our customers with a single point of contact to help them create integrated solutions for this special patient population, from concept to delivery.”

The whole solution is greater than the sum of its parts. The radiolucent table, surgical lighting, equipment management system, mini-integration system and high-definition monitors combine seamlessly to provide better visualization and excellent imaging for neonatal procedures. Critical information is available right in front of the surgeon and the system’s remote connectivity capability can link the waiting family directly with the room so they can observe the procedure.

The synergistic efforts of STERIS and NeoForce have resulted in a unique, seamless platform for neonatal procedures that helps surgeons achieve optimal patient outcomes. This collaboration is one of a series of strategic agreements STERIS has formed with leading surgical solutions providers to develop customized solutions for various surgical and intervention specialties. STERIS equipment management and integration technologies are designed with an open architecture, which lend themselves to collaboration and flexible design.

### **About STERIS**

STERIS Corporation is a leading provider of infection prevention and surgical products and services, focused primarily on critical healthcare, pharmaceutical and research markets. The Company's approximately 5,000 dedicated employees around the world work together to supply a broad array of equipment, consumables and services solutions that enhance Customer productivity and quality and help make the world a safer place. The Company is listed on the New York Stock Exchange under the symbol STE. For more information, please visit [www.steris.com](http://www.steris.com).

### **About NeoForce**

NeoForce™ Group, Inc., a Delaware Corporation, is a medical device company serving the neonatal/perinatal area of the global hospital market. Our primary focus is to deliver value-added capital products and services to allow for the care of the premature or special needs infant. The

NeoForce Group's strength lies with its experienced management team and a proven track record of identifying unmet clinical needs and creating cost-effective solutions.

####

*This news release may contain statements concerning certain expectations, forecasts, estimates, product performance or other forward-looking information affecting or relating to the Company or its products and services that are intended to qualify for the protections afforded "forward-looking statements" under the Private Securities Litigation Reform Act of 1995 and other laws and regulations. Forward-looking statements speak only as to the date of this release, and may be identified by the use of forward-looking terms such as "may," "will," "expects," "believes," "anticipates," "plans," "new," "advanced," and "best available," or the negative of such terms or other variations on such terms or comparable terminology. Many important factors could cause actual results to differ materially from those in this news release including, without limitation, disruption of production or supplies, changes in product use, pending or future claims, technology advances, and changes in government regulations or the application or interpretation thereof. No assurances can be provided as to any product performance or product safety unless all labeling, instructions for use, MSDS and other product literature are strictly followed. Unless legally required, the Company does not undertake to update or revise any forward-looking statements even if events make clear that any projected results, express or implied, will not be realized. Other potential risks and uncertainties that could cause actual results to differ materially from those in this news release include, without limitation, (a) the possibility that market demand will not develop for new technologies, products or applications; (b) the possibility that application of or compliance with laws, court rulings, regulations, certifications or other requirements or standards may delay or prevent product introductions or otherwise affect product performance; or (c) uses not consistent with product instructions. Product descriptions and performances herein are for illustration only and do not modify labeling, warranties or other technical literature.*